How developing world concerns need to be part of drug development plans: a case study of four emerging antiretrovirals

Drug Discovery Today

Volumn 13, Issue 13-14, 2008, Pages 601-605

  van Roey, Jens ^a   von Schoen Angerer, Tido ^a   Ford, Nathan ^a   Calmy, Alexandra ^a,b  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b Geneva Children's Hospital   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; ETRAVIRINE; INTELENCE; MARAVIROC; NEVIRAPINE; RALTEGRAVIR; RILPIVIRINE;

CENTRAL NERVOUS SYSTEM DISEASE; DEVELOPING COUNTRY; DRUG APPROVAL; DRUG COST; DRUG RESEARCH; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRACTICE GUIDELINE; REVIEW; WORLD HEALTH ORGANIZATION;

ANTI-RETROVIRAL AGENTS; DEVELOPING COUNTRIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; HUMANS; RETROVIRIDAE INFECTIONS;

EID: 45949100482     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2008.04.009     Document Type: Review

References (27)

1. World Health Organization. Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach (2006), WHO
2. Ford N., et al. Treating HIV in the developing world: getting ahead of the drug development curve. Drug Discov. Today 12 (2007) 1-3
3. Nathan C. Aligning pharmaceutical innovation with medical need. Nat. Med. 13 (2007) 304-308
4. Khoo S., et al. The potential for interactions between antimalarial and antiretroviral drugs. AIDS 19 (2005) 995-1005
5. FDA Modernization Act of 1997 (http://www.fda.gov/cder/guidance/105-115.html)
6. Regulation (EC) No. 1901/2006 of the European Parliament and of the council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No. 726/2004 (http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/vol1/reg_2006_1 901/reg_2006_1901_en.pdf)
7. Treatment Action Group (2007) The 2007 pipeline report. In Experimental Treatments and Preventive Therapies for HIV, Hepatitis C, and Tuberculosis. TAG (http://www.aidsinfonyc.org/tag/tx/pipeline0707.pdf)
8. Pozniak A. 48-week primary analysis of trial TMC278-C204: TMC278 demonstrates potent and sustained efficacy in ART-naïve patients. 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, 25-28 February (2007) (Abstract #144LB)
9. Esté J., and Telenti A. HIV entry inhibitors. Lancet 370 (2007) 81-88
10. Dayam R. HIV-1 integrase inhibitors, an emerging clinical reality. Drugs in R&D 8 (2007) 155-168
11. Cahn P., et al. Pooled 24-week results of DUET-1 and -2: TMC125 vs placebo in 1203 treatment-experienced HIV-1-infected patients. Program and Abstracts of the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago, Illinois, 17-20 September (2007) (Abstract H-717)
12. Saag M., et al. A multicenter, randomized, double-blind, comparative trial of a novel CCR5 antagonist, maraviroc versus efavirenz, both in combination with Combivir (zidovudine [ZDV]/lamivudine [3TC]), for the treatment of antiretroviral naive patients infected with R5 HIV 1: week 48 results of the MERIT study. 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. Sydney, Australia, 22-25 July, 2007 (2007) (Abstract WESS104)
13. Yeni P., et al. TMC278, a next-generation NNRTI, demonstrates potent and sustained efficacy in ARV-naive patients: week 48 primary analysis of study TMC278-C204. 11th European AIDS Conference. Madrid (2007) (Abstract P7.2/08)
14. Antiviral Solid Dispersions. European Patent Office. International Publication Number: WO 2001/022938 (05.04.2001, Gazette 2001/14)
15. Pinheiro E., et al. Examining the production costs of antiretroviral drugs. AIDS 20 (2006) 1745-1752
16. Marzolini C., et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 5 (2001) 71-75
17. Woodfall B., et al. Impact of NNRTI and NRTI resistance on the response to the regimen of TMC125 Plus 2 NRTIs in study TMC125-227. Eighth International Congress on Drug Therapy in HV Infection. Glasgow, 12-16 November (2006) (Abstract PL5.6)
18. Cohen C., et al. Efficacy and safety results at 48 weeks with the novel NNRTI, TMC125, and impact of baseline resistance on the virologic response in study TMC125-C223. 16th International AIDS Conference. Toronto, Canada, 13-18 August (2006) (Abstract No. TuPE0061)
19. Cahn P. Raltegravir: a new antiretroviral class for salvage therapy. Lancet 369 (2007) 1261-1269
20. Product Information: ISENTRESS oral tablets, raltegravir oral tablets (2007), Merck & Co., Inc., Whitehouse Station, NJ
21. van Heeswijk, R. et al. (2006) The effects of CYP3A4 modulation on the pharmacokinetics of TMC278, an investigational non-nucleoside reverse transcriptase inhibitor. Poster 47, 7th International Workshop of Clinical Pharmacology, April 2006 (Abstract 74)
22. European Medicines Agency. Committee for medicinal products for human use. Summary of Positive Opinion for Celsentri. EMEA/CHMP/255299/2007 (http://www.emea.europa.eu/pdfs/human/opinion/Celsentri_25529907en.pdf)
23. Tseng, A. (2007) Drug Interactions with CCR5 Antagonists. Toronto General Hospital (http://www.tthhivclinic.com/pdf/CCR5-int.pdf)
24. Cleary S., et al. The cost-effectiveness of antiretroviral treatment in Khayelitsha, South Africa - a primary data analysis. Cost Effect. Resour. Allocat. 4 (2006) 4-20
25. Chokshi D.A., and Rajkumar R. Leveraging university research to advance global health. JAMA 298 (2007) 1934-1936
26. Ford N., and Torreele E. Neglected diseases of global importance. JAMA 286 (2001) 23
27. Moran M., et al. Partnership dynamics, issues and challenges. Global Forum Update on Research for Health Vol. 4 (2007), Global Forum for Health Research